Press Releases

 

Company News

  Date Title and Summary View
May 12, 2017
LAWRENCEVILLE, N.J., May 12, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the quarter ended March 31, 2017 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-...
May 5, 2017
LAWRENCEVILLE, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter ended March 31, 2017 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxo...
May 4, 2017
LAWRENCEVILLE, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced updated additional clinical and translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of ne...
Apr 20, 2017
LAWRENCEVILLE, N.J., April 20, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients wi...
Apr 13, 2017
Higher Concentrations of Doxorubicin Accumulation and Distribution within the Bladder Wall Were Achieved with ThermoDox® Combined with Mild Local Hyperthermia Compared to Free Doxorubicin Alone The Study Reinforces ThermoDox's Unique, Proprietary Mechanism of Action LAWRENCEVILLE, N.J., April 13, 2017 (GLOBE NEWSWIRE) -- Celsion Corpo...
Mar 16, 2017
LAWRENCEVILLE, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today announced financial results for the year ended December 31, 2016 and provided an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GE...
Mar 9, 2017
LAWRENCEVILLE, N.J., March 09, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss year-end 2016 financial results and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation of doxorubicin and GEN-1, an...
Feb 27, 2017
OVATION Study Fully Enrolled, Final Patient Enrolled in the Fourth Cohort Complete Clinical and Translational Research Data to be Announced During the Second Quarter LAWRENCEVILLE, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Khursheed Anwer, Ph.D., Celsion's executive vice president and ch...
Feb 15, 2017
LAWRENCEVILLE, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced the pricing of a public offering with expected total gross proceeds of approximately $5.0 million. The offering was priced at $0.23 per share of common stock (or common stock equivalent), with each share of common stock (o...
Jan 19, 2017
LAWRENCEVILLE, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium being held from February 23 - 25, 2017 in Orlando, FL.  The symposium will foc...
Page:
1
... NextLast
= add release to Briefcase
Share This